For the nine months ended September 30, 2012, net sales were $52,536,938, compared with $46,096,813 in the comparable prior-year period, an increase of 14%. Advanced wound care sales were $17,126,374 for the nine months ended September 30, 2012, an increase of 49%. Excluding sales of MedEfficiency products from both periods, sales of advanced wound care products grew 30%. The Company reported a net loss of $8,385,956 or $0.69 per share for the nine months ended September 30, 2012, compared with a net loss of $1,887,615 or $0.23 per share in the prior-year period.As of September 30, 2012, Derma Sciences had cash, cash equivalents and investments of $15,620,234, compared with cash, cash equivalents and investments of $22,584,350 at December 31, 2011.
Derma Sciences Reports Third Quarter 2012 Financial Results
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.